Video

Dr. Jadvar shares highlights of appropriate use criteria for PSMA PET imaging

Author(s):

Urology Times staff

“PSMA is a very exciting development in the field of nuclear medicine,” says Hossein Jadvar, MD, PhD.

In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, provides an overview of the appropriate use criteria that he helped to develop for prostate-specific membrane antigen PET imaging. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.

Related Videos
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Modern medical office interior with computer and examination table | Image Credit: © New Africa - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Illuccix approved in Europe for detection of PSMA-positive lesions
January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke
The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Conventional imaging may understage prostate cancer, new data suggest
January 3rd 2025

Conventional imaging may understage prostate cancer, new data suggest

Hannah Clarke
“However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases," says Adrien Holzgreve, MD, MHA.
[99mTc]Tc-HYNIC-iPSMA shows promise in prostate cancer imaging
January 3rd 2025

[99mTc]Tc-HYNIC-iPSMA shows promise in prostate cancer imaging

Hannah Clarke
The detection rate for [99mTc]Tc-HYNIC-iPSMA SPECT imaging was 77.5%.
TLX250-CDx BLA resubmitted to FDA for kidney cancer
January 2nd 2025

TLX250-CDx BLA resubmitted to FDA for kidney cancer

Hannah Clarke
The BLA for TLX250-CDx was initially submitted to the FDA in June 2024.
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
© 2025 MJH Life Sciences

All rights reserved.